4547 Kissei Pharmaceutical
- 3195
- +50+1.59%
Kissei Pharmaceutical News
Nichibatalyst, Recruit HD, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|--------------|<7550＞|Zensho HD | Morgan S | “Equal W” | “Over W” | “Over W” | Downgrade-Bearish Code | Stock Name | Securities Company | Conventional | After the Change |----
Yunlou Stock List (Weekly Chart) [Ichimoku Equilibrium Chart/Cloud Stock List]
○Cloud Top Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜2281＞ Prima Ham 2409 2341 2304 ＜2288＞ Marudaishoku 1672 1617.5 1570.5 ＜2307＞ Crosscat 1322 1076.25 1266 ＜2371＞ Kaka
Ando and Mama, Fudo Tetra, etc.
＜1433＞Vestera Co., Ltd. Yoshino Heiki Stock Ownership Ratio 14.92% → 14.47% Reporting Obligation Date 2024/04/26 ＜1518＞Mitsui Matsushima Holdings Co., Ltd. Nomura Securities Co., Ltd. Stock Ownership Ratio 5.40% → 5.20% Reporting Obligation Date 2024/05/15 ＜1719＞Ando Ma Co., Ltd. Jupiter Asset Management Limited (Jupiter Asset Management Limited)
J-Front, Kissei Pharmaceutical Industries, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|-----------------------------|----------|-------|＜4205＞|Nippon Zeon |SMBC Nikko |1500 yen |1600 yen |＜8056＞|BIPROGY | SMBC Nikko | 3600 yen
List of Unrivaled Stocks (Part 2) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○List of unscathed stocks market code stock name closing price advance span A advance span B Tokyo stock prime ＜1887＞ Japan Land Development 520 523 565.5 ＜1899＞ Fukuda Gumi 5350 5580 5445 ＜2282＞ Nichi-Ham 5085 5212.25 5091.5 ＜2327＞
Stocks that moved the day before part 1 e-Guardian, Insource, Charm Care, etc.
<コード>Stock name 8-day closing price ⇒ compared to the previous day Yusen ＜9101＞ 4480 +175 stock repurchase announcement with an upper limit of 7.6% of the number of issued shares. AGC＜5201＞ 5244-592 1st quarter operating profit decreased by 29.5%. Toyota ＜7203＞ 3579 - operating profit for the fiscal year ending 2025/3 is expected to decrease 19.7%. Stock buybacks and cancellations were also announced. Stock prices don't have a sense of direction. LINTEC ＜7966＞ 3450 +26025 operating profit for the fiscal year ending March 31 is expected to increase 69.4%. Shinnichi Kagaku <239
Kissei Pharmaceutical: Financial results briefing materials for the fiscal year ending 2024/3
Kissei Pharmaceutical's Attributable Profit Jumps 6% in Fiscal 2023; Shares Tumble 11%
Kissei Pharmaceutical (TYO:4547) posted a 6% jump in consolidated profit attributable to owners in fiscal 2023, thanks to higher net sales, lower operating costs, and the recording of extraordinary in
Volume change rate ranking (around 9 o'clock) ~ Unicharm, Nintendo, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/8 9:32 as of 9:32] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate ＜2525＞ NZAM 225 7821 107185.08 136.95% -0.005% ＜
5/8 [Today's Investment Strategy]
[FISCO Specially Selected Brand] [Material Brand] E-Guardian ＜6050＞ 1375 yen (5/7) We carry out real-time posting monitoring work, online game customer support work, etc. A change in the dividend policy was announced, and it is said that dividends will be distributed using a consolidated dividend ratio of about 30% as a guide. Along with this, the year-end dividend (= annual dividend) for the fiscal year ending 24/9 will be 31 yen. The previous forecast was 27 yen, and the previous fiscal year was 26 yen. At the same time, it was announced that a new shareholder benefit system would be established. Also, they announced financial results for the first half
Pay attention to Kawasaki Ships and Unicharm, are Nintendo and Kissei drugs doing well
The NY Dow rose by 31.99 dollars to 38,884.26 in the US stock market yesterday 7th, the Nasdaq Composite Index fell 16.70 points to 16,332.55, and the Chicago Nikkei 225 futures were 38,715 yen lower than the Osaka Japan-China ratio. The exchange rate is 1 dollar = 154.60-70 yen. In today's Tokyo market, operating income for the current fiscal year is expected to decrease by 0.2%, but the Japan Stock Exchange (8511), which announced stock buybacks with an upper limit of 2.0% of the number of issued shares, announced that operating income is expected to increase 18.2% for the previous fiscal year and 32.7% for the current fiscal year
Nintendo's 24/3 operating profit increased 4.9% to 528.9 billion yen, 25/3 forecast decreased 24.4% to 400 billion yen
The financial results for the fiscal year ending 2024/3 announced by Nintendo ＜7974＞ were sales of 1.671,865 billion yen, up 4.4% from the previous fiscal year, and operating profit of 528.941 billion yen, up 4.9% from the same period. As for the financial results for the fiscal year ending 2025/3, we plan that sales will decrease 19.3% from the previous fiscal year to 1.35 trillion yen, and operating profit will decrease 24.4% to 400 billion yen. Sales related to the main engine “Nintendo Switch,” which has reached its 8th year of sale, will slow down. It falls below consensus (about 490 billion yen). [Positive Assessment] <61
Kissei Pharmaceutical: Supplementary Financial Information for the Fiscal Year Ending March 31, 2024
Kissei Pharmaceutical: Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
JFEHD, Yokogawa Electric, Nintendo, Kawasaki Ships (7 days)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/7 (Tue) ＜130A＞VIS ＜1333＞Maruha Nichiro ＜1723＞NEC ＜2003＞Nitto Fuji ＜2009＞Torigoe Powder ＜2053＞Chubukai ＜2281＞Prima Ham ＜2344＞Heian Rei ＜290
No plans (6 days) [Earnings Schedule]
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/6 (Mon) ---------------------------------------5/7 (Tue) ＜130A＞VIS ＜1333＞Maruha Nichiro ＜1723＞NEC ＜2003＞Nitto Fuji ＜2009＞Torigoe powder
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1417＞ Miraite One 1906 1988＜1939＞ Yodenko 3840 4030 ＜1941＞ Chudenko 3165 3460 ＜1961＞ Sankiko 2175 2279 ＜2327＞ NSSOL
Convertible Stock List [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1417＞ Miraitone 1939 1849 ＜1518＞ Mitsui Matsushima HD 3075 2853 ＜1815＞ Tekken 2695 2555 ＜1950＞ Nippon Densetsu 2114 2031 ＜1969＞ Takasago Fever 4930 4575
Endometriosis Global Clinical Trials Review 2024, Featuring AbbVie, Bayer, Ferring Holding, Neurocrine Biosciences, Sumitomo, Takeda Pharmaceutical, Kissei Pharmaceutical, Pfizer and Astellas Pharma - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Endometriosis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of
Kissei Pharmaceutical 9-Mos Net Y8.34B Vs Net Y6.67B
Kissei Pharmaceutical Co. Ltd. (4547.TO) Japan Nine Months Ended December 31 GROUP 2023 2022 Revenue Y57.86 bln Y51.64 bln Operating Profit Y4.1
Analysis
Price Target
No Data
